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Introduction {#sec006}
============

There are several important risk factors for developing ischemic heart disease (IHD), including diabetes, hypertension, dyslipidemia, smoking and obesity \[[@pone.0173898.ref001]--[@pone.0173898.ref007]\]. Among the risk factors, cholesterol is a major component of the deposits that can narrow the coronary arteries. A high level of low-density lipoprotein (LDL) cholesterol in the blood may be due to an inherited condition or a diet high in saturated fats and cholesterol. Among cholesterol profiles, oxidized low-density lipoprotein (Ox-LDL) plays a pivotal role in the pathogenesis of atherosclerosis. Malondialdehyde-modified low-density lipoprotein (MDA-LDL) has been modified by MDA, leading to the production of a large amount of aldehyde when LDL degenerates and is oxidized \[[@pone.0173898.ref008]\]. It is known that the MDA-LDL level is elevated in patients with dyslipidemia and diabetes mellitus. Recently, MDA-LDL has been widely accepted as an important risk factor of IHD in general \[[@pone.0173898.ref009], [@pone.0173898.ref010]\].

It is important to take acute coronary syndrome (ACS) symptoms seriously as it is a life-threatening condition. Although ACS generally occurs in the background of atherosclerosis \[[@pone.0173898.ref011]--[@pone.0173898.ref013]\], ACS with no relevant narrowing of the coronary artery is a frequently occurring syndrome with a heterogeneous pathogenesis. Recently, the importance of inflammation and collagen metabolism has been recognized \[[@pone.0173898.ref014]\]. In addition, it is hypothesized that coronary spasm contributes to the onset of ACS to a greater or lesser degree in most cases \[[@pone.0173898.ref007], [@pone.0173898.ref015]--[@pone.0173898.ref017]\]. Nevertheless, patients occasionally do not experience ACS attacks despite the extensive progression of organic stenosis or calcification in the coronary arteries. Therefore, more precise mechanisms of atherosclerotic plaque initiation and progression, the methods by which plaques suddenly precipitate life-threatening thrombi, and the concepts of plaque burden, activity, and vulnerability should continue to be studied.

It is accepted that the progression of organic stenosis in the coronary arteries and the onset of ACS occur similarly in the development of atherosclerosis and that common risk factors therefore exist for both clinical conditions. However, the extent of each association to the progression of organic stenosis or ACS has not been elucidated. The risk factors might have different tendencies toward susceptibility to the progression of organic stenosis or onset of ACS.

A difficult aspect of this kind of study is how to design the study for simultaneous comparison of plural risk factors for respective pathological conditions. To the best of our knowledge, there is no report that uses such a complex study design. If possible, simultaneous analysis would be very helpful in gaining a deeper understanding of the characteristics of these risk factors. This new understanding will provide an efficient approach to the prevention and therapy of IHD in each individual.

Covariance structure analysis plays an important role in understanding how the relationship among observed variables might be generated by hypothesized latent variables in many areas. Covariance structure analysis is also useful for exploratory and explanatory factor analysis. When planning such an analysis, the input factors should be carefully selected. The path model, which is based on covariance structure analysis, should be proposed based on a well-defined concept and a clear direction of the study. Recently, we reported our research using covariance structure analysis in a tangible way \[[@pone.0173898.ref018]\].

We investigated the similarities and differences in the risk factors between the progression of organic stenosis in coronary arteries and the onset of ACS using covariance structure analysis in patients with IHD who were admitted consecutively to our institution. In this study, we aimed to clarify to which condition, organic stenosis or ACS, each risk factor is more likely linked and in particular to delineate more efficient prevention and therapy approaches for ACS in the future.

Methods {#sec007}
=======

Study patients {#sec008}
--------------

The study population consisted of 1,029 patients with IHD who were admitted consecutively to our institution between 2012 and 2015. These patients underwent emergency cardiac catheterization upon admission or during the chronic phase. IHD was diagnosed based on the clinical features and examination findings, including the criteria of ischemic ECG changes and a blood test, following the universal definition of 2012\[[@pone.0173898.ref019]\]. In a practical sense, we diagnosed IHD in our institution as follows: in brief, (1) a history of chest pain, oppression, or discomfort lasting 20 min or longer. (2) A typical electrocardiographic change (i.e., ST segment elevation greater than 0.1 mV in at least 1 standard lead or 2 precordial leads, ST segment depression greater than 0.1 mV in at least 2 leads, or abnormal Q waves or T-wave inversions in at least 2 leads). (3) An increased serum level of the MB fraction of creatine kinase equivalent to more than twice the upper limit of the normal range or cardiac troponin T detected in blood using a TROPT^®^ sensitive rapid test strip. Patients without elevated biomarker values can be diagnosed as having unstable angina. According to these criteria, we could diagnose the study patients of acute coronary syndrome more precisely as having unstable angina pectoris (UAP), ST segment elevation myocardial infarction (STEMI), and non-ST segment elevation myocardial infarction (NSTEMI). In addition, stable angina pectoris was diagnosed when patients did not have angina at rest but had findings indicative of IHD based on exertional angina, ECG changes, and the morphology of the coronary arteries.

For the purpose of this study, we categorized the study patients in two ways. The first was to categorize the patients into ACS and non-ACS groups. The anamnestic history of a previous experience of ACS was irrelevant. The degree of coronary organic stenosis was also irrelevant in this method of classification.

The second categorization was based on the degree of organic stenosis in the coronary arteries. We counted the branch of the diseased vessels with organic stenosis of 75% and more; then, we divided the patients into four groups based on the number of diseased vessels: 0, 1, 2, or 3 vessels. The current and previous admitting status of ACS or non-ACS was irrelevant in this classification. Patients with coronary spasm induced by a provocation test with intracoronary injection of acetylcholine were categorized in the 0-vessel group if there was no organic stenosis after nitroglycerin administration.

Patients who previously received coronary intervention and/or coronary artery bypass grafting were excluded from the study population. This study was approved by the ethics committee of the Jikei University School of Medicine (study protocol: 24--150\[6916\]), and we complied with the routine ethical regulations of our institution as follows: this is a retrospective study and informed consent could not be obtained from each patient. Instead of informed consent from each patient, we publicly posted a notice regarding the study design and contact information at a publicly known place in our institution.

Blood sampling and measurement of biochemical examination {#sec009}
---------------------------------------------------------

Blood sampling was conducted for every patient with IHD during cardiac catheterization. Serum biochemical analyses were performed in a central laboratory in our hospital.

Statistical analysis {#sec010}
--------------------

Continuous variables were expressed as the means ± standard deviation (SD) or the median. Statistical analyses were performed using IBM SPSS Statistics version 23.0 (SPSS Inc., Chicago, IL, USA). Multiple regression analysis was adopted on an as-needed basis. Path analysis based on covariance structure analysis was used to investigate the relationship among clinical factors in this study population and particularly to identify probable causal effects in organic stenosis or ACS. Path analysis was performed using IBM SPSS AMOS version 23 (Amos Development Corporation, Meadville, PA, USA). The obtained structural equation models were tested and confirmed at the significance level for *P* values of \<0.05. The implementation procedures of covariance structure analysis have been described previously \[[@pone.0173898.ref018]\].The causality model defines certain hierarchical regression models that compare clinical factors in organic stenosis and ACS. When obtaining critical ratios for differences between parameters, AMOS supplies a matrix with a row and column for each parameter of the model. Each off-diagonal entry in the provides gives a statistic for testing the hypothesis that two model parameters are equal in the population.

Results {#sec011}
=======

Study patient characteristics {#sec012}
-----------------------------

Among the 1,029 patients with IHD, 310 patients were diagnosed as ACS and 719 patients as non-ACS at admission. Of the total 1,029 patients, 252 patients had 0-vessel disease, 453 patients had 1-vessel disease, 212 patients had 2-vessel disease, and 112 patients had 3-vessel disease. Additional characteristics of the non-ACS and ACS groups are shown in [Table 1](#pone.0173898.t001){ref-type="table"}.

10.1371/journal.pone.0173898.t001

###### Patient characteristics of non-ACS and ACS groups.

![](pone.0173898.t001){#pone.0173898.t001g}

  N = 1,029                Non-ACS        ACS
  ------------------------ -------------- ---------------------------------------------------
  Number of patients (%)   719 (69.9)     310 (30.1)
  Age                      65.5 ± 10.5    64.5 ± 13.1
  Male, gender (%)         621 (86.4)     244 (78.7)
  BMI, kg/m^2^             24.6 ± 3.7     24.3 ± 4.2
  Smoker (%)               180 (25.0)     95 (30.6)
  HbA1c, %                 6.3 ± 1.0      6.3 ± 1.3
  LDL, mg/dℓ               103.7 ± 30.2   117.9 ± 39.2[\*](#t001fn001){ref-type="table-fn"}
  HDL, mg/dℓ               51.8 ± 15.3    53.6 ± 17.2
  MDA-LDL, U/L             120.3 ± 41.0   154.2 ± 69.5[\*](#t001fn001){ref-type="table-fn"}
  Underlying diseases                     
  Diabetes mellitus (%)    307 (42.7)     109 (35.2)[\*](#t001fn001){ref-type="table-fn"}
  Hypertension (%)         543 (75.5)     230 (74.1)
  Dyslipidemia (%)         531 (73.9)     222 (71.6)
  Diseased vessel (%)                     
  0VD                      180 (25.0)     72 (23.2)
  1VD                      310 (43.1)     143 (46.1)
  2VD                      152 (21.1)     60 (19.3)
  3VD                      77 (10.7)      35 (11.3)
  UAP (%)                                 168 (54.2)
  NSTEMI (%)                              42 (13.5)
  STEMI (%)                               100 (32.3)
  Medication (%)                          
  Statin                   385 (53.5)     79 (25.5)[\*](#t001fn001){ref-type="table-fn"}
  CCB                      416 (57.9)     117 (37.7)[\*](#t001fn001){ref-type="table-fn"}
  β-blocker                266 (37.0)     34 (11.0)[\*](#t001fn001){ref-type="table-fn"}
  ACE/ARB                  175 (24.3)     108 (34.3)[\*](#t001fn001){ref-type="table-fn"}
  Antiplatelet             226 (31.4)     85 (27.4)

\*: *P* \< 0.05: vs. non-ACS group.

ACS = acute coronary syndrome; BMI = body mass index; HbA1c = hemoglobin A1c; LDL = low-density lipoprotein cholesterol; HDL = high-density lipoprotein cholesterol; MDA-LDL = malondialdehyde-modified low-density lipoprotein; 0VD = 0-vessel disease; 1VD = single-vessel disease; 2VD = double-vessel disease; 3VD = triple-vessel disease; UAP = unstable angina pectoris; NSTEMI = non-ST segment elevation myocardial infarction; STEMI = ST segment elevation myocardial infarction; CCB = calcium channel blocker; β-blocker = beta blocker; ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker

Multivariate analysis for determination of risk factors of the onset of ACS or the progression of CAD {#sec013}
-----------------------------------------------------------------------------------------------------

The several potential risk factors, which were listed as candidates based on previous information, were included in the analysis; age, gender, HbA1c, high-density lipoprotein (HDL), LDL, MDA-LDL, smoking, hypertension and body mass index (BMI) were used as dependent variables (Tables [2](#pone.0173898.t002){ref-type="table"} and [3](#pone.0173898.t003){ref-type="table"}). We adopted multiple logistic regression analysis by using 0 as the independent value for non-ACS and 1 for ACS. As a result, multivariate analysis revealed that male gender, high HDL and high MDA-LDL represented the risks for ACS ([Table 2](#pone.0173898.t002){ref-type="table"}). Multiple linear regression analysis was adapted for determination of the diseased vessels. As a result, multivariate analysis revealed that age, male gender, HbA1c, low HDL, high LDL and hypertension represented risks or CAD ([Table 3](#pone.0173898.t003){ref-type="table"}). Thus, MDA-LDL would represent a risk for ACS but not for organic stenosis. In contrast, HbA1c represented a risk for organic stenosis but not for ACS. However, these respective multivariate analyses would still be inadequate for interpreting the risk factors correctly because the factors are expected to confound each other and because it is challenging to make the characteristics of each risk factor explicit using the respective equation models (i.e., not using a unified equation model).

10.1371/journal.pone.0173898.t002

###### Multivariate analysis for determination of ACS.

![](pone.0173898.t002){#pone.0173898.t002g}

           Regression coefficients   Standard error   *P* value   Odds ratio
  -------- ------------------------- ---------------- ----------- ------------
  Gender   -0.47                     0.20             0.02        0.63
  HDL      0.01                      0.01             0.01        1.01
  MDALDL   0.01                      0.00             0.00        1.01

Objective variable: ACS or non-ACS

Explanatory variable: age, gender, HbA1c, HDL, LDL, MDALDL, smoking, hypertension, BMI, Non-significant variables: age, HbA1c, LDL, smoking, hypertension, BMI

ACS = acute coronary syndrome; HbA1c = hemoglobin A1c; HDL = high-density lipoprotein cholesterol; LDL = low-density lipoprotein cholesterol; MDA-LDL = malondialdehyde-modified low-density lipoprotein; BMI = body mass index

10.1371/journal.pone.0173898.t003

###### Multivariate analysis for diseased vessels.

![](pone.0173898.t003){#pone.0173898.t003g}

                 Regression coefficients   Standard error   Test statistic   *P* value
  -------------- ------------------------- ---------------- ---------------- -----------
  Age            0.012                     0.002            5.54             \<0.001
  Gender         0.235                     0.061            3.825            \<0.001
  HbA1c          0.091                     0.02             4.571            \<0.001
  HDL            -0.005                    0.001            -3.186           0.001
  LDL            0.006                     0.001            6.339            \<0.001
  Hypertension   0.102                     0.05             2.03             0.043

Objective variable: the number of diseased vessels

Explanatory variable: age, gender, HbA1c, HDL, LDL, MDALDL, smoking, hypertension, BMI

Non-significant variables: MDA-LDL, smoking, BMI

HbA1c = hemoglobin A1c; HDL = high-density lipoprotein cholesterol; LDL = low-density lipoprotein cholesterol; MDA-LDL = malondialdehyde-modified low-density lipoprotein; BMI = body mass index

Concept of Path model A {#sec014}
-----------------------

The proposed path model is shown in [Fig 1](#pone.0173898.g001){ref-type="fig"}. Logically, the risk factors are expected to potentially confound each other; the association between two factors is linked by the two-way arrows. Paths between variables are drawn from independent to dependent variables, with a directional arrow for every regression model, namely, from age, gender, HbA1c, HDL,LDL, MDA-LDL, smoking, hypertension, and BMI to the diseased vessels and to ACS. In the analysis, the two-way arrow between the degree of organic stenosis and ACS (namely, e1--e2) was of intrinsic importance. In the path model, the number of diseased vessels was counted as 0, 1, 2 or 3, respectively.

![Proposed Path model A.\
The path has estimates of standardized regression weights and estimates of correlations among exogenous variables. The variable (given in parentheses) means "not statistically significant." HbA1c = hemoglobin A1c; HDL-C = high-density lipoprotein cholesterol; LDL = low-density lipoprotein; MDA-LDL = malondialdehyde-modified LDL; HDL = high-density lipoprotein; HT = hypertension; BMI = body mass index.](pone.0173898.g001){#pone.0173898.g001}

Results of Path model A: Estimation of regression weights in organic stenosis {#sec015}
-----------------------------------------------------------------------------

[Table 4](#pone.0173898.t004){ref-type="table"} shows the estimates of regression weights and estimates of standardized regression weights. The analysis using the path model to examine the risk factors for the advancement of organic stenosis revealed that age (standardized regression coefficient; β: 0.206, *P* \< 0.001), male gender (β: 0.126, *P* \< 0.001), HbA1c (β: 0.109, *P* \< 0.001) and LDL ((β: 0.127, *P* \< 0.001) were the significant factors. Note that MDA-LDL is not statistically correlated with advancement of organic stenosis (*P* = NS).

10.1371/journal.pone.0173898.t004

###### Path model A: Estimates of regression weight and standard regression weight.

![](pone.0173898.t004){#pone.0173898.t004g}

  Clinical Factor                  Estimate   Standard error   Test statistic   P Value   Standard regression coefficient   
  -------------------------------- ---------- ---------------- ---------------- --------- --------------------------------- -------
  ACS (R^2^ = 0.107)               \<\--Age   0.000            0.001            0.016     0.987                             0.001
  \<\--Gender                      -0.101     0.039            -2.563           0.010     -0.081                            
  \<\--HbA1c                       -0.006     0.012            -0.491           0.624     -0.015                            
  \<\--HDL                         0.003      0.001            3.128            0.002     0.100                             
  \<\--LDL                         0.000      0.001            -0.847           0.397     -0.034                            
  \<\--MDALDL                      0.003      0.000            8.166            \<0.001   0.335                             
  \<\--Smoking                     0.035      0.032            1.099            0.272     0.034                             
  \<\--HT                          0.004      0.032            0.118            0.906     0.004                             
  \<\--BMI                         -0.004     0.004            -0.906           0.365     -0.030                            
  Diseased Vessel (R^2^ = 0.086)   \<\--Age   0.017            0.003            5.985     \<0.001                           0.206
  \<\--Gender                      0.319      0.080            3.959            \<0.001   0.126                             
  \<\--HbA1c                       0.090      0.025            3.591            \<0.001   0.109                             
  \<\--HDL                         -0.006     0.002            -3.381           \<0.001   -0.109                            
  \<\--LDL                         0.003      0.001            3.160            0.002     0.127                             
  \<\--MDALDL                      0.000      0.001            -0.104           0.917     -0.004                            
  \<\--Smoking                     0.120      0.066            1.828            0.068     0.057                             
  \<\--HT                          0.061      0.066            0.922            0.357     0.028                             
  \<\--BMI                         -0.010     0.008            -1.186           0.236     -0.040                            

ACS = acute coronary syndrome; HbA1c = hemoglobin A1c; HDL = high-density lipoprotein cholesterol; LDL = low-density lipoprotein cholesterol; MDA-LDL = malondialdehyde-modified low-density lipoprotein; HT = hypertension; BMI = body mass index

Results of Path model A: Estimation of regression weights in ACS {#sec016}
----------------------------------------------------------------

As also shown in [Table 4](#pone.0173898.t004){ref-type="table"}, the analysis using the path model to examine the risk factors for ACS revealed that gender (β: −0.081, *P* = 0.010), HDL (β: 0.100, *P* = 0.002) and MDA-LDL (β: 0.355, *P* \< 0.001) were the significant factors. Considering the power of β, it is of note that the significance of MDA-LDL was substantially higher than that of other factors. This finding was statistically confirmed by critical ratios for the differences between parameters; MDA-LDL was more strongly associated than any other parameter with ACS (*P* \< 0.01, respectively), which was examined in the matrix for each parameter of this model. (The full matrix is not shown due to size constraints.)

Results of Path model A: Association among relative risk factors {#sec017}
----------------------------------------------------------------

[Table 5](#pone.0173898.t005){ref-type="table"} shows the results of estimates of covariance among exogenous variables and estimates of correlations among exogenous variables. Among them, the association between LDL and MDA-LDL was prominent (β; 0.652, *P \<* 0.001). The association between organic stenosis and ACS (namely, e1--e2) was of importance; the *P* value was not significant (*P* = 0.851).

10.1371/journal.pone.0173898.t005

###### Path model A: Association between relative risk factors.

![](pone.0173898.t005){#pone.0173898.t005g}

  Clinical factor   Estimate   Standard error   Test statistic   *P* value   Standard regression coefficient             
  ----------------- ---------- ---------------- ---------------- ----------- --------------------------------- --------- --------
  BMI               \<\--\>    Age              -14.835          1.435       -10.335                           \<0.001   -0.341
  \<\--\>           Gender     0.386            0.045            8.503       \<0.001                           0.275     
  \<\--\>           HbA1c      0.601            0.136            4.421       \<0.001                           0.140     
  \<\--\>           HDL        -16.225          1.971            -8.233      \<0.001                           -0.266    
  \<\--\>           LDL        6.604            4.047            1.632       0.103                             0.051     
  \<\--\>           MDALDL     25.504           6.455            3.951       \<0.001                           0.124     
  \<\--\>           Smoking    0.211            0.053            3.963       \<0.001                           0.125     
  \<\--\>           HT         0.158            0.052            3.044       0.002                             0.095     
  HT                \<\--\>    Age              0.809            0.155       5.209                             \<0.001   0.165
  \<\--\>           Gender     0.000            0.005            0.039       0.969                             0.001     
  \<\--\>           HbA1c      0.009            0.015            0.580       0.562                             0.018     
  \<\--\>           HDL        -0.589           0.216            -2.733      0.006                             -0.086    
  \<\--\>           LDL        -0.690           0.456            -1.513      0.130                             -0.047    
  \<\--\>           MDALDL     -0.371           0.722            -0.513      0.608                             -0.016    
  \<\--\>           Smoking    -0.012           0.006            -2.045      0.041                             -0.064    
  Smoking           \<\--\>    Age              -1.461           0.163       -8.946                            \<0.001   -0.291
  \<\--\>           Gender     0.021            0.005            4.164       \<0.001                           0.131     
  \<\--\>           HbA1c      0.010            0.016            0.632       0.527                             0.020     
  \<\--\>           HDL        -0.591           0.221            -2.678      0.007                             -0.084    
  \<\--\>           LDL        1.180            0.468            2.521       0.012                             0.079     
  \<\--\>           MDALDL     3.543            0.748            4.739       \<0.001                           0.149     
  MDALDL            \<\--\>    Age              -135.825         19.454      -6.982                            \<0.001   -0.223
  \<\--\>           Gender     0.357            0.612            0.583       0.560                             0.018     
  \<\--\>           HbA1c      4.198            1.887            2.225       0.026                             0.070     
  \<\--\>           HDL        -179.680         27.197           -6.607      \<0.001                           -0.211    
  \<\--\>           LDL        1179.820         67.406           17.503      \<0.001                           0.652     
  LDL               \<\--\>    Age              -53.013          12.093      -4.384                            \<0.001   -0.138
  \<\--\>           Gender     -1.163           0.388            -3.001      0.003                             -0.094    
  \<\--\>           HbA1c      0.583            1.188            0.491       0.624                             0.015     
  \<\--\>           HDL        -0.088           16.792           -0.005      0.996                             0.000     
  HDL               \<\--\>    Age              25.174           5.700       4.417                             \<0.001   0.139
  \<\--\>           Gender     -1.119           0.185            -6.042      \<0.001                           -0.192    
  \<\--\>           HbA1c      -1.760           0.562            -3.130      0.002                             -0.098    
  HbA1c             \<\--\>    Age              0.279            0.399       0.699                             0.484     0.022
  \<\--\>           Gender     0.038            0.013            2.940       0.003                             0.092     
  Gender            \<\--\>    Age              -0.814           0.132       -6.155                            \<0.001   -0.196
  e1                \<\--\>    e2               0.002            0.012       0.188                             0.851     0.006

HbA1c = hemoglobin A1c; HDL = high-density lipoprotein cholesterol; LDL = low-density lipoprotein cholesterol; MDA-LDL = malondialdehyde-modified low-density lipoprotein; HT = hypertension; BMI = body mass index

Results of Path model A: Critical ratios of differences between parameters (risk factors associated with organic stenosis or ACS) {#sec018}
---------------------------------------------------------------------------------------------------------------------------------

Among the risk factors, the critical ratios for differences between parameters were examined via the matrix. Age, LDL, and HbA1c were more strongly associated with organic stenosis than ACS (*P* \< 0.01, respectively); in contrast, the MDA-LDL level was more strongly associated with ACS than diseased vessels (*P* \< 0.01). (The full matrix is not shown due to size constraints.)

Concept of Path model B and the results {#sec019}
---------------------------------------

Next, Path model B was developed in a similar way to Path model A by dividing the ACS patients into three groups: unstable angina pectoris (UAP), non-ST segment elevation myocardial infarction (NSTEMI) and ST segment elevation myocardial infarction (STEMI) groups, as shown in [Fig 2](#pone.0173898.g002){ref-type="fig"}. MDA-LDL was associated with UAP and STEMI. There was, however, no statistically significant association between MDA-LDL and NSTEMI ([Table 6](#pone.0173898.t006){ref-type="table"}).

10.1371/journal.pone.0173898.t006

###### Path model B: Estimates of regression weight and standard regression weight.

![](pone.0173898.t006){#pone.0173898.t006g}

  Clinical Factor                  Estimate   Standard error   Test statistic   P Value   Standard regression coefficient   
  -------------------------------- ---------- ---------------- ---------------- --------- --------------------------------- --------
  Diseased Vessel (R^2^ = 0.086)   \<\--Age   0.017            0.003            5.993     \<0.001                           0.206
  \<\--Gender                      0.319      0.080            3.965            \<0.001   0.126                             
  \<\--HbA1c                       0.090      0.025            3.603            \<0.001   0.110                             
  \<\--HDL                         -0.006     0.002            -3.388           \<0.001   -0.110                            
  \<\--LDL                         0.003      0.001            3.166            0.002     0.128                             
  \<\--MDALDL                      0.000      0.001            -0.106           0.916     -0.004                            
  \<\--Smoking                     0.120      0.066            1.831            0.067     0.058                             
  \<\--HT                          0.061      0.066            0.923            0.356     0.028                             
  \<\--BMI                         -0.010     0.008            -1.188           0.235     -0.040                            
  UAP (R^2^ = 0.055)               \<\--Age   -0.001           0.001            -0.603    0.547                             -0.021
  \<\--Gender                      -0.072     0.033            -2.209           0.027     -0.072                            
  \<\--HbA1c                       -0.023     0.010            -2.231           0.026     -0.069                            
  \<\--HDL                         0.003      0.001            3.739            \<0.001   0.123                             
  \<\--LDL                         -0.001     0.000            -1.294           0.196     -0.053                            
  \<\--MDALDL                      0.002      0.000            5.196            \<0.001   0.220                             
  \<\--Smoking                     0.004      0.027            0.135            0.892     0.004                             
  \<\--HT                          0.031      0.027            1.155            0.248     0.036                             
  \<\--BMI                         -0.003     0.003            -0.756           0.449     -0.026                            
  NSTEMI (R^2^ = 0.020)            \<\--Age   -0.001           0.001            -0.939    0.348                             -0.033
  \<\--Gender                      0.013      0.018            0.753            0.451     0.025                             
  \<\--HbA1c                       0.003      0.006            0.581            0.561     0.018                             
  \<\--HDL                         0.000      0.000            1.017            0.309     0.034                             
  \<\--LDL                         0.001      0.000            2.277            0.023     0.095                             
  \<\--MDALDL                      0.000      0.000            1.094            0.274     0.047                             
  \<\--Smoking                     -0.017     0.015            -1.137           0.256     -0.037                            
  \<\--HT                          -0.002     0.015            -0.163           0.870     -0.005                            
  \<\--BMI                         -0.001     0.002            -0.443           0.657     -0.016                            
  STEMI (R^2^ = 0.049)             \<\--Age   0.001            0.001            1.409     0.159                             0.049
  \<\--Gender                      -0.042     0.026            -1.611           0.107     -0.052                            
  \<\--HbA1c                       0.014      0.008            1.650            0.099     0.051                             
  \<\--HDL                         0.000      0.001            -0.640           0.522     -0.021                            
  \<\--LDL                         0.000      0.000            -1.207           0.228     -0.050                            
  \<\--MDALDL                      0.001      0.000            5.052            \<0.001   0.214                             
  \<\--Smoking                     0.048      0.021            2.251            0.024     0.072                             
  \<\--HT                          -0.025     0.022            -1.147           0.251     -0.036                            
  \<\--BMI                         0.000      0.003            -0.116           0.908     -0.004                            

ACS = acute coronary syndrome; UAP = unstable angina pectoris; NSTEMI = non-ST segment elevation myocardial infarction; STEMI = ST segment elevation myocardial infarction; HbA1c = hemoglobin A1c; HDL = high-density lipoprotein cholesterol; LDL = low-density lipoprotein cholesterol; MDA-LDL = malondialdehyde-modified low-density lipoprotein; HT = hypertension; BMI = body mass index

![Proposed Path model B (sub-group analysis of acute coronary syndrome).\
The path has estimates of standardized regression weights and estimates of correlations among exogenous variables. The variable (given in parentheses) means "not statistically significant." UAP = unstable angina pectoris; STEMI = ST segment elevation myocardial infarction; NSTEMI = non-ST segment elevation myocardial infarction; HbA1c = hemoglobin A1c; HDL-C = high-density lipoprotein cholesterol; LDL = low-density lipoprotein; MDA-LDL = malondialdehyde-modified LDL; HDL = high-density lipoprotein; HT = hypertension; BMI = body mass index.](pone.0173898.g002){#pone.0173898.g002}

Concept of Path model C and the results {#sec020}
---------------------------------------

Finally, Path model C was proposed, as shown in [Fig 3](#pone.0173898.g003){ref-type="fig"}. The possible drug effects on the current study were taken into consideration. The analysis revealed that LDL, age and HbA1c were significant for the advancement of organic stenosis. The MDA-LDL level was significant for the onset of ACS. Thus, the main results in Path model C were not affected by the applied medication and were similar to those in Path model A. In this path model, only as a guide, antiplatelet therapy was effective in suppressing both ACS and organic stenosis (Tables [7](#pone.0173898.t007){ref-type="table"} and [8](#pone.0173898.t008){ref-type="table"}).

10.1371/journal.pone.0173898.t007

###### Path model C: Estimates of regression weight and standard regression weight.

![](pone.0173898.t007){#pone.0173898.t007g}

  Clinical Factor                  Estimate     Standard error   Test statistic   P Value   Standard regression coefficient   
  -------------------------------- ------------ ---------------- ---------------- --------- --------------------------------- --------
  ACS (R^2^ = 0.315)               \<\--HbA1c   -0.001           0.011            -0.084    0.933                             -0.002
  \<\--LDL                         -0.001       0.000            -1.819           0.069     -0.064                            
  \<\--MDALDL                      0.002        0.000            5.941            \<0.001   0.205                             
  \<\--CCB                         -0.026       0.026            -1.005           0.315     -0.028                            
  \<\--β-blocker                   -0.149       0.027            -5.528           \<0.001   -0.148                            
  \<\--Antiplatelet                -0.388       0.028            -13.768          \<0.001   -0.405                            
  \<\--ACE/ARB                     -0.021       0.026            -0.821           0.411     -0.023                            
  \<\--Statin                      -0.048       0.027            -1.777           0.076     -0.052                            
  Diseased Vessel (R^2^ = 0.041)   \<\--HbA1c   0.103            0.026            4.026     \<0.001                           0.125
  \<\--LDL                         0.003        0.001            2.365            0.018     0.098                             
  \<\--MDALDL                      0.001        0.001            0.741            0.459     0.030                             
  \<\--CCB                         0.027        0.062            0.430            0.667     0.014                             
  \<\--β-blocker                   0.048        0.064            0.752            0.452     0.024                             
  \<\--Antiplatelet                0.205        0.067            3.042            \<0.001   0.106                             
  \<\--ACE/ARB                     0.032        0.062            0.521            0.603     0.018                             
  \<\--Statin                      0.019        0.064            0.305            0.760     0.010                             

ACS = acute coronary syndrome; HbA1c = hemoglobin A1c; LDL = low-density lipoprotein cholesterol; MDA-LDL = malondialdehyde-modified low-density lipoprotein; CCB = calcium channel blocker; β-blocker = beta blocker; ACE = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker

10.1371/journal.pone.0173898.t008

###### Path model C: Association between relative risk factors.

![](pone.0173898.t008){#pone.0173898.t008g}

  Clinical factor   Estimate       Standard error   Test statistic   P value   Standard regression coefficient            
  ----------------- -------------- ---------------- ---------------- --------- --------------------------------- -------- --------
  Statin            \<\--\>        HbA1c            0.031            0.018     1.771                             0.077    0.055
  \<\--\>           LDL            -5.509           0.552            -9.981    \<0.001                           -0.328   
  \<\--\>           MDALDL         -6.691           0.857            -7.806    \<0.001                           -0.251   
  \<\--\>           CCB            0.047            0.008            5.99      \<0.001                           0.19     
  \<\--\>           β-blocker      0.032            0.007            4.465     \<0.001                           0.141    
  \<\--\>           Antiplatelet   0.086            0.008            10.838    \<0.001                           0.359    
  \<\--\>           ACE/ARB        0.049            0.008            6.238     \<0.001                           0.198    
  ACE/ARB           \<\--\>        HbA1c            0.036            0.018     2.05                              0.04     0.064
  \<\--\>           LDL            -2.039           0.531            -3.841    \<0.001                           -0.121   
  \<\--\>           MDALDL         -3.365           0.842            -3.997    \<0.001                           -0.126   
  \<\--\>           CCB            0.085            0.008            10.303    \<0.001                           0.339    
  \<\--\>           β-blocker      0.043            0.007            5.91      \<0.001                           0.188    
  \<\--\>           Antiplatelet   0.065            0.008            8.437     \<0.001                           0.273    
  Antiplatelet      \<\--\>        HbA1c            0.02             0.017     1.213                             0.225    0.038
  \<\--\>           LDL            -3.524           0.517            -6.823    \<0.001                           -0.218   
  \<\--\>           MDALDL         -6.276           0.823            -7.621    \<0.001                           -0.245   
  \<\--\>           CCB            0.064            0.008            8.255     \<0.001                           0.266    
  \<\--\>           β-blocker      0.049            0.007            7.082     \<0.001                           0.226    
  β-blocker         \<\--\>        HbA1c            0.019            0.016     1.216                             0.224    0.038
  \<\--\>           LDL            -1.194           0.481            -2.485    0.013                             -0.078   
  \<\--\>           MDALDL         -1.546           0.761            -2.031    0.042                             -0.063   
  \<\--\>           CCB            0.025            0.007            3.493     \<0.001                           0.11     
  CCB               \<\--\>        HbA1c            -0.039           0.018     -2.203                            0.028    -0.069
  \<\--\>           LDL            -2.14            0.531            -4.03     \<0.001                           -0.127   
  \<\--\>           MDALDL         -2.952           0.84             -3.515    \<0.001                           -0.11    
  MDALDL            \<\--\>        HbA1c            4.21             1.887     2.231                             0.026    0.07
  \<\--\>           LDL            1179.82          67.406           17.503    \<0.001                           0.652    
  HbA1c             \<\--\>        LDL              0.578            1.188     0.487                             0.627    0.015
  e1                \<\--\>        e2               0.021            0.011     1.922                             0.055    0.06

HbA1c = hemoglobin A1c; LDL = low-density lipoprotein cholesterol; MDA-LDL = malondialdehyde-modified low-density lipoprotein; CCB = calcium channel blocker; β-blocker = beta blocker; ACE = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker

![Proposed Path model C (Potential influence of drugs).\
The path has estimates of standardized regression weights and estimates of correlations among exogenous variables. The variable (given in parentheses) means "not statistically significant." HbA1c = hemoglobin A1c; HDL-C = high-density lipoprotein cholesterol; LDL = low-density lipoprotein; MDA-LDL = malondialdehyde-modified LDL; HDL = high-density lipoprotein; HT = hypertension; BMI = body mass index. ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; CCB = calcium channel blocker.](pone.0173898.g003){#pone.0173898.g003}

Discussion {#sec021}
==========

In this study, we investigated the differences in the risk factors between the progression of organic stenosis and the onset of ACS using covariance structure analysis. First, this study showed that the link between the organic stenosis and ACS groups (e1--e2) was not statistically significant, as shown in [Table 5](#pone.0173898.t005){ref-type="table"}. In addition, there were substantial differences in the contribution of risk factors to organic stenosis or ACS. HbA1c and LDL were strong risk factors for the advancement of organic stenosis, whereas MDA-LDL showed a substantial risk for ACS. The contribution of MDA-LDL to organic stenosis was not significant in this study. Previous findings showed MDA-LDL to be risk factor of IHD in general \[[@pone.0173898.ref008]--[@pone.0173898.ref010]\]. However, an unambiguous strong association between MDA-LDL and ACS had not been previously reported, and the current study is the first to clearly show, in a parallel comparison, the distinct effect of MDA-LDL on the onset of ACS rather than on the advancement of organic stenosis.

The precise mechanisms of the close correlation between MDA-LDL and ACS are unknown at present, although it is probable that endothelial dysfunction is the core mechanism. Endothelial dysfunction is widely accepted as the earliest event in atherosclerosis \[[@pone.0173898.ref020]\]. Ox-LDL is known to enhance the expression of pro-inflammatory molecules, leading to monocyte recruitment in the vessel wall. Ox-LDL is cytotoxic to endothelial cells via the generation of free radicals and impairs nitric oxide synthase gene expression and its activity. Ox-LDL triggers the activation of an inflammatory signaling pathway and increases gene expression and the activity of matrix metalloproteinases in endothelial cells \[[@pone.0173898.ref021]\]. It is also notable that Ox-LDL-associated endothelial dysfunction induces coronary spasms, even though LDL itself is not necessarily associated with coronary spasms \[[@pone.0173898.ref007]\].

The relatively strong risk factors associated with organic stenosis were age, HbA1c and LDL. The mechanism of the strong contribution of HbA1c to the advancement of organic stenosis, but not to ACS, is of interest. We speculate that diabetes contributes to the vascular smooth muscle cell (VSMC) phenotype. VSMCs can perform both contractile and synthetic functions, which are associated with and characterized by changes in morphology, proliferation, and migration rates and the expression of different marker proteins \[[@pone.0173898.ref022]--[@pone.0173898.ref024]\]. Diabetes-induced vascular complications are associated with VSMC phenotypic modulation, which involves switching from a contractile to a synthetic-proliferative phenotype \[[@pone.0173898.ref025]\]. Diabetes induces organic stenosis in coronary arteries, but VSMC phenotypic changes may suppress vascular hyper-contractility. Although diabetes may cause a thick plaque cap, stabilizing plaque rupture, coronary stenosis is gradually augmented. In the design of this study, we did not include insulin resistance data (such as homeostasis model assessment of insulin resistance \[HOMA-IR\]). Insulin resistance is frequently associated with endothelial dysfunction and has been proposed to play a pivotal role in cardiovascular diseases. Insulin sensitizations that target pathway-selective impairment in insulin signaling are known to improve endothelial dysfunction \[[@pone.0173898.ref026]\]. A cross-comparison with HOMA-IR may result in a different conclusion from that of this study based on a separate mechanism from HbA1c

BMI is known to be a risk factor for atherosclerosis \[[@pone.0173898.ref027]\]; however, BMI was not significant in our analysis and exhibited a lack of statistical power exhibited both organic stenosis and ACS. Although the precise reason is currently unclear, the following reasons are proposed. The study population was not severely obese, and the mean BMI in this study was much lower than that of Caucasians. It is probable that mild obesity has a low potential to cause harm, but obesity should beget other risks, such as diabetes, hypertension, and dyslipidemia. Clarification of the true contribution of obesity to IHD and heart failure is eagerly anticipated.

Among the results shown in [Table 4](#pone.0173898.t004){ref-type="table"}, we found another curious result: high HDL was associated with ACS, although low HDL was unsurprisingly associated with diseased vessels. We cannot explain this result at present; however, according to a recent report, HDL function may be impaired in such a patient with ACS \[[@pone.0173898.ref028]\].

Patients in the current study with ACS consisted of those with unstable angina and myocardial infarction. We proposed a path modeling approach in which the ACS patients were divided into three groups, namely, UAP, STEMI and NSTEMI, to examine the contribution of MDA-LDL in more detail. As shown in Path model B, MDA-LDL was strongly associated with UAP and STEMI but not with NSTEMI. Rather, there was a weak but significant association of LDL with NSTEMI. Therefore, the risks of NSTEMI may be similar to those of organic stenosis from the perspective of dyslipidemia.

In this study, we proposed Path model C to examine the effects of drugs on the current findings. There was a significant association of MDA-LDL level with ACS and of HbA1c level and LDL with organic stenosis. Although this path modeling may not be able to fully eliminate the influence of drugs, the analysis indicated no influence of drugs on the current findings.

This study shows that for immediate risk avoidance, the MDA-LDL level is a suitable marker and possibly the more appropriate target of treatment. A potential therapeutic regimen in targeting MDA-LDL would be a use of strong statin to adequately decrease both LDL and MDA-LDL levels. Smoking cessation is an important component of this treatment \[[@pone.0173898.ref029]\].

There are several limitations of our study. The triglyceride level is commonly affected after a meal; such levels were omitted from our study based on the assumption that some patients probably ate shortly before their emergency admission. Thus, the impact of triglycerides is still unknown. Second, cigarette smoking and alcohol intake might have been underestimated in this study. It is probable that these two factors are linked more strongly to the onset of ACS because they often enhance the activity of coronary spasms in the Japanese \[[@pone.0173898.ref007],[@pone.0173898.ref015],[@pone.0173898.ref016]\]. Third, although we believe that the current path model provides new information, especially regarding the importance of MDA-LDL in ACS, the square of the multiple correlation coefficient was 0.086 for organic stenosis as an estimated value and 0.107 for ACS. This result indicates that there are many other factors associated with the progression of organic stenosis and the onset of ACS that should be clarified in the future.

In conclusion, the current statistical analysis showed clear differences among the risk factors between the progression of organic stenosis and the onset of ACS. Among them, the MDA-LDL level should be considered to represent a substantial risk of ACS.
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